

# Ototoxicity rates in children receiving carboplatin studied

29 February 2012



associated with an increased incidence of hearing loss. The different ototoxicity grading systems showed good overall agreement for identifying ototoxicity, and agreement was greatest between the Brock and Children's Cancer Group systems.

"Young patients with [retinoblastoma](#) who were treated with systemic [carboplatin](#) had a higher incidence of ototoxicity than previously reported," the authors write.

**More information:** [Abstract](#)

[Full Text \(subscription or payment may be required\)](#)  
[Editorial](#)

(HealthDay) -- Retinoblastoma patients who are younger than 6 months of age at the start of carboplatin treatment experience a higher incidence of ototoxicity, according to a study published online Feb. 27 in the *Journal of Clinical Oncology*.

Copyright © 2012 [HealthDay](#). All rights reserved.

Ibrahim Qaddoumi, M.D., of the St. Jude Children's Research Hospital in Memphis, Tenn., and colleagues reviewed the results of audiologic tests for 60 patients with retinoblastoma who received front-line treatment with systemic carboplatin and vincristine according to either the St. Jude RET-3 protocol (23 patients) or best [clinical management](#) (37 patients). Three different ototoxicity grading systems were used.

The researchers found that 12 patients (20 percent) developed ototoxicity at some point following initiation of treatment; ototoxicity resolved in two patients, leaving 10 patients (17 percent) with sustained hearing loss. Nine of these 10 patients had grade 3 or 4 ototoxicity. Ninety percent of the 10 patients with hearing loss were less than 6 months of age at the start of chemotherapy. Age at the start of chemotherapy was the only risk factor that significantly predicted sustained hearing loss, and younger age was

APA citation: Ototoxicity rates in children receiving carboplatin studied (2012, February 29) retrieved 4 May 2021 from <https://medicalxpress.com/news/2012-02-ototoxicity-children-carboplatin.html>

*This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.*